Results 91 to 100 of about 719,508 (214)
Cardiotoxicity of BRAF/MEK inhibitors
British Journal of Pharmacology, EarlyView.Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source
ErbB targeted therapy in endometrial cancer
, 2015 The Epidermal Growth Factor system is present in human organs and play important role in cell proliferation, differentiation and apoptosis during embryogenesis and postnatal development.
Adonakis Georgios +2 more
core +2 more sources
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Roles of ErbB-3 and ErbB-4 in the Physiology and Pathology of the Mammary Gland
, 1997 ErbB-3 and ErbB-4 are the most recently discovered and least characterized of the class I tyrosine kinase receptors. ErbB-3 is noteworthy for its low tyrosine kinase activity, suggesting that it may function more as an adaptor in signaling than as a ...
Carraway, Kermit +2 more
core +1 more source
, 1998 The four receptor tyrosine kinase I receptors, ErbB-1, ErbB-2, ErbB-3, and ErbB-4, which have been implicated in the development of a variety of normal and malignant tissues, are activated through ligand mediated homo- and heterodimerization.
Lunec J +7 more
core +4 more sources
BMC Cancer, 2012 Background Acquired resistance to endocrine therapy in breast cancer is a significant problem with relapse being associated with local and/or regional recurrence and frequent distant metastases.
Hiscox Stephen +9 more
doaj +1 more source
Cancer Science, EarlyView.WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka +15 more
wiley +1 more source
Journal of Anatomy, EarlyView.CADM1 and CADM2 are related cell‐adhesion molecules that show differential patterns of expression in early human fetal forebrain. Although often co‐expressed in neurons, CADM2 protein exclusively and selectively localises to axons, whereas CADM1 is predominantly expressed in the nucleus, posing questions as to what their developmental roles might be ...
Natalie Wucherer +4 more
wiley +1 more source
Drug Design, Development and Therapy, 2018 Dehua Liao,1,2 Yujin Guo,3 Daxiong Xiang,2 Ruili Dang,3 Pengfei Xu,3 Hualin Cai,2 Lizhi Cao,1 Pei Jiang3 1Department of Pharmacy, Hunan Cancer Hospital, 2Department of Pharmacy, Institute of Clinical Pharmacy & Pharmacology, Second Xiangya Hospital,
Liao D +7 more
doaj